Cytokinetics has revealed the results from a phase 3 trial of its hypertrophic cardiomyopathy (HCM) drug aficamten that it hopes will allow it to compete with Bristol-Myers Squibb’s first-to-market ...
24 Sep 2021 15 Oct 2021 29 Oct 2021 Fourth interim dividend of 0.5 sen per ordinary share 14 Oct 2021 29 Nov 2021 21 Jan 2022 31 Jan 2022 Final dividend of 0.5 sen per ordinary share 20 Jan 2022 16 ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果